News & Updates

Show Multimedia Only
Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 byStephen Padilla

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

27 Oct 2023
Roflumilast serves up weight-loss benefit for patients with psoriasis

Roflumilast serves up weight-loss benefit for patients with psoriasis

20 Oct 2023 byJairia Dela Cruz

In the treatment of patients with psoriasis, the phosphodiesterase (PDE)-4 inhibitor roflumilast has been found to also induce weight loss.

20 Oct 2023
Newly diagnosed T2D linked to earlier CVD events

Newly diagnosed T2D linked to earlier CVD events

20 Oct 2023

A new diagnosis of type 2 diabetes (T2D) raises the risk of cardiovascular disease (CVD) development within 10 years in both men and women and across age groups, particularly among younger patients, reveals a recent study.

20 Oct 2023